PURPOSE: The primary aim of this study was to assess pulmonary radiation toxicity quantitatively in patients who received thoracic radiotherapy combined with induction and/or concurrent chemotherapy with or without taxanes for esophageal cancer. METHODS AND MATERIALS: The study subjects were 139 patients treated at the University of Texas M.D. Anderson Cancer Center for esophageal cancer and who had undergone [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography between November 1, 2003 and December 15, 2007 for disease restaging after chemoradiotherapy. The patients were grouped into those who had not received taxanes (Group 1), those who had received induction or concurrent taxanes (Group 2), and those who had received both induction and concurrent taxanes (Group 3). Clinical pulmonary toxicity was scored using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. Linear regression was applied to the fluorodeoxyglucose uptake vs. radiation dose to determine the pulmonary metabolic radiation response (PMRR) for each case. The clinical toxicity scores and PMRR among the groups were evaluated for significance differences. RESULTS: The crude rate of pneumonitis symptoms was 46%, 62%, and 74% for Group 1, 2, and 3, respectively. The analysis of variance test of log(PMRR) by treatment was significant (p = .0046). Group 3 had a 61% greater PMRR compared with Group 1 (p = .002). Group 2 had a 38% greater PMRR compared with Group 1 (p = .015). Finally, Group 3 had a 17% greater PMRR compared with Group 2 (p = .31). A PMRR enhancement ratio of 1.60 (95% confidence interval, 1.19-2.14) was observed for Group 3 vs. Group 1. CONCLUSION: Patients given induction and concurrent taxane chemotherapy had a significantly greater PMRR and clinical pneumonitis symptoms compared with the patients whose chemotherapy regimen did not include taxanes. Copyright (c) 2010 Elsevier Inc. All rights reserved.
PURPOSE: The primary aim of this study was to assess pulmonary radiation toxicity quantitatively in patients who received thoracic radiotherapy combined with induction and/or concurrent chemotherapy with or without taxanes for esophageal cancer. METHODS AND MATERIALS: The study subjects were 139 patients treated at the University of Texas M.D. Anderson Cancer Center for esophageal cancer and who had undergone [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography between November 1, 2003 and December 15, 2007 for disease restaging after chemoradiotherapy. The patients were grouped into those who had not received taxanes (Group 1), those who had received induction or concurrent taxanes (Group 2), and those who had received both induction and concurrent taxanes (Group 3). Clinical pulmonary toxicity was scored using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. Linear regression was applied to the fluorodeoxyglucose uptake vs. radiation dose to determine the pulmonary metabolic radiation response (PMRR) for each case. The clinical toxicity scores and PMRR among the groups were evaluated for significance differences. RESULTS: The crude rate of pneumonitis symptoms was 46%, 62%, and 74% for Group 1, 2, and 3, respectively. The analysis of variance test of log(PMRR) by treatment was significant (p = .0046). Group 3 had a 61% greater PMRR compared with Group 1 (p = .002). Group 2 had a 38% greater PMRR compared with Group 1 (p = .015). Finally, Group 3 had a 17% greater PMRR compared with Group 2 (p = .31). A PMRR enhancement ratio of 1.60 (95% confidence interval, 1.19-2.14) was observed for Group 3 vs. Group 1. CONCLUSION:Patients given induction and concurrent taxane chemotherapy had a significantly greater PMRR and clinical pneumonitis symptoms compared with the patients whose chemotherapy regimen did not include taxanes. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: P Wong; A N Leung; G J Berry; K A Atkins; J G Montoya; S J Ruoss; F E Stockdale Journal: AJR Am J Roentgenol Date: 2001-03 Impact factor: 3.959
Authors: J A Ajani; R Komaki; J B Putnam; G Walsh; J Nesbitt; P W Pisters; P M Lynch; A Vaporciyan; R Smythe; S Lahoti; I Raijman; S Swisher; F D Martin; J A Roth Journal: Cancer Date: 2001-07-15 Impact factor: 6.860
Authors: A G Taghian; S I Assaad; A Niemierko; I Kuter; J Younger; R Schoenthaler; M Roche; S N Powell Journal: J Natl Cancer Inst Date: 2001-12-05 Impact factor: 13.506
Authors: Youseff M Hanna; Kathleen L Baglan; Jannifer S Stromberg; Frank A Vicini; David A Decker Journal: Breast J Date: 2002 May-Jun Impact factor: 2.431
Authors: Justin P Hart; Matthew R McCurdy; Muthuveni Ezhil; Wei Wei; Meena Khan; Dershan Luo; Reginald F Munden; Valen E Johnson; Thomas M Guerrero Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-19 Impact factor: 7.038
Authors: Paiman Ghafoori; Lawrence B Marks; Zeljko Vujaskovic; Christopher R Kelsey Journal: Oncology (Williston Park) Date: 2008-01 Impact factor: 2.990
Authors: Thomas Guerrero; Josue Martinez; Matthew R McCurdy; Michael Wolski; Mary Francis McAleer Journal: Int J Radiat Oncol Biol Phys Date: 2011-03-04 Impact factor: 7.038
Authors: Bernhard J Leibl; Stephanie Vitz; Wolfgang Schäfer; Martin Alfrink; Andreas Gschwendtner; Gerhard G Grabenbauer Journal: Strahlenther Onkol Date: 2011-03-24 Impact factor: 3.621
Authors: Daniel R Gomez; Susan L Tucker; Mary K Martel; Radhe Mohan; Peter A Balter; Jose Luis Lopez Guerra; Hongmei Liu; Ritsuko Komaki; James D Cox; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2012-08-21 Impact factor: 7.038
Authors: Alfredo E Echeverria; Matthew McCurdy; Richard Castillo; Vincent Bernard; Natalia Velez Ramos; William Buckley; Edward Castillo; Ping Liu; Josue Martinez; Thomas Guerrero Journal: Radiother Oncol Date: 2012-11-02 Impact factor: 6.280
Authors: James Welsh; Stephen H Settle; Arya Amini; Lianchun Xiao; Akihiro Suzuki; Yuki Hayashi; Wayne Hofstetter; Ritsuko Komaki; Zhongxing Liao; Jaffer A Ajani Journal: Cancer Date: 2011-10-05 Impact factor: 6.860
Authors: Matthew R McCurdy; Richard Castillo; Josue Martinez; Mohammad Najeeb Al Hallack; Jessica Lichter; Nicolas Zouain; Thomas Guerrero Journal: Radiother Oncol Date: 2012-05-10 Impact factor: 6.280
Authors: Richard Castillo; Ngoc Pham; Sobiya Ansari; Dmitriy Meshkov; Sarah Castillo; Min Li; Adenike Olanrewaju; Brian Hobbs; Edward Castillo; Thomas Guerrero Journal: Radiat Oncol Date: 2014-03-13 Impact factor: 3.481